Exosome marketing claims come down to single words. One soft verb or one button can turn an education page into an offer for a product with no FDA approval. This post is a word-level reference for clinics that want to publish exosome education. It covers the words to use, the words to cut, and why hedges like “supports” no longer pass.
TLDR: No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products. That leaves no room for exosome marketing claims, only education. Since the FDA’s October 13, 2026 warning letter, hedged words like “supports,” “promotes” and “may aid” are out for exosome, cord and placental products. Below is a Do Use and Do Not Use list. Run it against your pages before counsel reads them.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, especially regarding FDA, FTC, and state-specific advertising regulations. Exosome marketing carries serious enforcement risk. Regen Portal is a marketing and consulting company, not a law firm.
When I read an exosome page, the problem is rarely one big claim. It is the small words. A heading says “healing.” An image tag says “exosome therapy for knees.” A button says “book now.”
This post is for clinics that want to publish exosome education. Offering the product is a separate question, and it is the bigger risk. That one belongs to your counsel.
Here we stay on the words: what to say, what to cut, and where claims hide on a page.
The Sentence Every Exosome Page Starts With
Every exosome education page starts with the status. Put it in the body, near the top. Use this sentence: No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products.
That comes from the FDA. Its consumer alert on stem cells and exosomes says there are currently no FDA-approved exosome products. Put the sentence in normal type, where every reader sees it. A footer note does not do this job.
What this means for your practice: The status sentence is the first fact on the page. Every other word on the page has to agree with it.
Why Soft Words Stopped Working in October 2026
Hedged words used to feel like a safe middle path. They are not. On October 13, 2026, the FDA’s biologics center sent a warning letter to an IV hydration brand. The brand sold stem cell and exosome IV packages.
The copy the letter quoted was all soft. It used words like “supports,” “promotes,” “may aid” and “could be beneficial.” The FDA still read it as intent to treat joint pain, arthritis, inflammation and damaged tissue. Hedging was not a defense.
So here is the rule now. “Supports,” “promotes,” “may aid” and “could be beneficial” are out for any exosome, cord or placental product. The FTC’s health products compliance guidance makes a related point. A softer verb does not replace the proof a health claim needs.
Mechanism words are out too. In August and September 2026, FDA letters to cord product suppliers quoted lines like “regulate inflammation” and “cells specialize.” They also cited cell counts per vial. Those letters were about cell products. I hold exosome copy to the same rule.
What this means for your practice: If a sentence says what the product does in the body, cut it. It does not matter how soft the verb is.
The Do Use and Do Not Use List for Exosome Copy
Here is the list I run against exosome copy. The left column is what to cut. The middle column says why. The right column is what can stand in its place, and sometimes the answer is nothing.
| Do Not Use | Why It Fails | Do Use Instead |
|---|---|---|
| “Exosome therapy for joint pain” | Names a condition for an unapproved product | “Exosomes are extracellular vesicles, tiny particles that cells release.” |
| “Supports healing” or “promotes recovery” | Hedged wording, out for exosome, cord and placental products since October 13, 2026 | Nothing. Cut the line. |
| “May aid inflammation” or “could be beneficial” | A hedge plus a condition | Nothing. Cut the line. |
| “Exosomes regulate inflammation” | A mechanism claim | “Exosomes carry proteins, lipids and RNA.” |
| “Research suggests exosomes may help” | A research claim with no data link, evidence grade or FDA line | “Scientists study exosomes to learn how cells signal to each other.” |
| “Off-label exosome therapy” | Off-label means an approved product used outside its label, and no exosome product is approved | “No exosome product is FDA approved for any use.” |
| “It’s a 361 product, so it’s exempt” | 361 needs all four criteria in 21 CFR 1271.10(a), and advertising counts | “The FDA treats exosomes used to treat disease as drugs and biological products.” |
| “Sourced from an FDA-registered lab” | Registration is not approval | Nothing. Keep supplier papers on file. |
| “Billions of exosomes per vial” | Counts per vial have drawn FDA letters for cell products | Nothing. Cut the line. |
| “Schedule a consult to discuss your options” | A booking prompt for an unapproved product | A link to the FDA’s own notice on exosome products |
| “Our patients love their results” | A testimonial works as an implied efficacy claim | Nothing. Cut the line. |
The bottom line: The Do Use column is short on purpose. Biology and status are what is left.
Our explainer on the 361 versus 351 test covers the 361 row in more depth. For the bigger picture on what a clinic can publish about exosomes at all, start there.
Where Exosome Claims Hide on a Page
Exosome marketing claims rarely sit only in the body copy. They hide in the places nobody reads twice. Check each of these:
- Page titles and headings. “Exosome Therapy” as a heading reads as a service. “What Exosomes Are” reads as education.
- Meta descriptions. The snippet in search results is ad copy, and the same rules apply.
- Image alt text. “Exosome injection for knee pain” is a condition claim inside a tag.
- Buttons and forms. A “book” or “schedule” button, or an exosome checkbox on a form, is a booking path.
- Menus and price lists. An exosome item on a service menu or IV menu is an offer, whatever the adjective.
- Social captions and video titles. Same words, same rules.
Search phrases like “exosome therapy near me” should lead to an education page, not a sales page. Our guide shows what an exosome education page holds and what it leaves out. Hair pages are a common trouble spot, and our post on exosome wording for hair loss pages goes line by line.
What this means for your practice: Search the whole site, including alt text, menus and forms, not just the page body.
Is There a Paid Route for Exosome Content?
No. For a clinic’s exosome content, I do not see a paid route. Google Ads does not accept exosome therapy advertising. Google’s ban on speculative and experimental treatments catches it. The policy page does not name exosomes, but the ban still applies.
The compliance rules I follow treat exosome ads as banned on every paid platform. Some regen services have a narrow educational path in Google Ads, and our Google Ads guide for regenerative medicine covers where it applies. Exosomes are not one of them.
What this means for your practice: Keep exosome education organic. Plan paid media around other services, and keep exosome words out of those ads too.
Run the Word Check Before a Page Goes Live
Before any exosome copy goes live, run a plain search. It is the fastest first pass I know, and it takes a few minutes.
- Search the page, headings, alt text, menus and forms. Look for these words: treat, heal, repair, regenerate, rejuvenate, therapy, treatment, supports, promotes, may aid, helps, results, off-label, registered, 361, consult, book, schedule and price.
- Cut or rewrite every hit, using the list above.
- Check that the status sentence sits in the body, near the top.
- Check that every FDA statement points to the FDA’s own page.
- Remove any path from the exosome page to an appointment, a form or a price.
- Send the final page to counsel, and keep the sign-off on file.
If a line survives the search, ask what proof stands behind it. Our post on what the FTC means by substantiation walks through that question. The same check is part of how we handle content creation for regen practices.
What this means for your practice: A word search will not catch everything. It will catch the words the FDA keeps quoting back to sellers.
Frequently Asked Questions
What Exosome Marketing Claims Can a Clinic Make?
None about what the product does. No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products. A clinic can publish biology and status, and nothing past that.
Do Words Like Supports or May Aid Still Work for Exosome Copy?
No. Since the FDA’s October 13, 2026 warning letter, hedged words like “supports,” “promotes” and “may aid” are out for any exosome, cord or placental product. The FDA read that kind of copy as intent to treat.
Can an Exosome Page Say Research Suggests a Benefit?
No. A research line needs a link to real data, the evidence grade and a line that the FDA has not evaluated the claim. Even with those, it points toward a benefit. On an exosome page, describe the biology instead.
Is It Accurate to Call Exosome Use Off-Label?
No. Off-label means an approved or cleared product used outside its label. No exosome product is approved, so the accurate word is unapproved.
Can an Exosome Page Include a Consult Button?
No. A consult button tells the reader the clinic provides exosomes. That turns the page into an offer for an unapproved product.
Where Do Exosome Claims Hide Besides the Body Copy?
Page titles, headings, meta descriptions, image alt text, buttons, forms, service menus, IV menus, price lists and social captions. Search all of them.
Can a Clinic Run Paid Ads for Exosome Education?
I would not plan on it. Google Ads does not accept exosome therapy advertising. The compliance rules I follow treat exosome ads as banned on every paid platform.
Key Takeaways
- No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products.
- There is no room for exosome marketing claims. What is left is biology and status.
- Supports, promotes and may aid no longer pass for exosome, cord and placental products.
- Mechanism words and counts per vial are out too.
- Off-label is the wrong word for exosomes. The accurate word is unapproved.
- Claims hide in headings, alt text, buttons, menus and forms. Search them all.
- No paid route exists for a clinic’s exosome content.
- Run the word check, then send the page to counsel.
PS: Build Exosome Content That Teaches
PS: Exosome content is the tightest rope in regen medicine. The product’s status sets the limit, and better framing does not move it. If you want help rebuilding exosome pages as education pages, it is what we do for regen practices. Reach out at hello@regenportal.com, or watch how we approach compliant regen marketing on YouTube and subscribe for weekly insights.
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
